Novel (heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives and use thereof as p75 inhibitors
The disclosure relates to (heterocycle/condensed piperidine)-(piperazinyl)-1-alkanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alkanone derivatives of the general formula (I), where A, W, n, and R2 are as defined in claim 1. The disclosure moreover relates to the method for preparing said derivatives and to the therapeutic use of said derivatives. Compounds of the disclosure include: 2-[8-(5-fluoropyrimidin-2-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-1-[2-(5-trifluoromethylpyridin-2-yl)-2,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl]ethanone 6-{ 3-[2-oxo-2-(1-phenyl-1,4,6,7-tetrahydropyrazolo[4,3-c]pyridin-5-yl)ethyl]-3,8-diazabicyclo[3.2.1]oct-8-yl} nicotinic acid 6-{ (2R,5S)-2,5-dimethyl-4-[2-oxo-2-(2-phenyl-6,7-dihydro-4Hthiazolo[5,4-c]pyridine-5-yl)ethyl]piperazin-1-yl} nicotinonitrile and 1-(2-methyl-2,4,6,7 -tetrahydropyrazolo[4,3-c]pyridin-5-yl)-2-[8-(5-trifluoromethylpyridin-2-yl)-3,8-diazabicyclo[3.2.1]oct-3-yl]ethanone.
